Analysis of 2,398 FDA adverse event reports for oral semaglutide tablets identified 93 significant safety signals, with gastrointestinal issues dominant and unexpected findings including thyroid cysts, acute cholecystitis, and abducens nerve paralysis.
93 safety signalsIdentified from 2,398 real-world FAERS reports for oral semaglutide tablets, including several unexpected adverse events
What the researchers found
From 2,398 FAERS reports (5,653 adverse events), 23 system organ classes and 93 preferred terms showed significant signals for oral semaglutide, with metabolism/nutrition disorders most signaled and unexpected findings of acute cholecystitis, abducens nerve paralysis, and positional vertigo.
Why it matters
As oral semaglutide becomes widely prescribed for diabetes and weight management, understanding its real-world safety profile beyond clinical trials is critical. The identification of unexpected adverse events like nerve paralysis and acute cholecystitis informs prescribers and patients.
The numbers in context
FAERS data covering 2019-2023 (4 years of post-marketing surveillance). GI events most frequently reported.
How the study worked
Retrospective analysis of FDA FAERS database (Q3 2019 to Q3 2023) for oral semaglutide. Data mining using four signal quantification methods: ROR, PRR, BCPNN, and MGPS for cross-validation.
Who was studied
Oral semaglutide users reported in FDA adverse event system
What this study cannot tell us
FAERS is a voluntary reporting system subject to reporting bias — not all adverse events are reported, and reports don't prove causation. The oral formulation's adverse event profile may partly reflect the unique absorption enhancer (SNAC) rather than semaglutide itself. Reporting rates are influenced by media attention and awareness.
How to read the evidence
Moderate evidence from a systematic analysis of the FDA's adverse event reporting database using four validated signal detection methods. FAERS data has inherent limitations including voluntary reporting and inability to establish causation.
When this study was published
Published in 2024, covering FAERS data from Q3 2019 (oral semaglutide approval) through Q3 2023.
The bigger picture
The GLP-1 drug class is being prescribed to tens of millions of people for diabetes and weight loss. Post-marketing surveillance like this FAERS analysis is essential for detecting rare side effects that clinical trials (typically enrolling thousands) might miss. The gallbladder and neurological signals align with emerging safety concerns across the GLP-1 class.
Questions still open
- Is the abducens nerve paralysis signal specific to oral semaglutide or shared with injectable forms?
- Does the oral formulation's absorption enhancer (SNAC) contribute to any of the observed GI adverse events?
- How do the safety signals change as the total number of users increases over time?
Common questions
Are the side effects of oral semaglutide different from the injectable version?
Should I be worried about these side effects?
Read the original research
Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(8), 1717-1733
Citation
Xiong, Si; Gou, Ruoyu; Liang, Xudong; Wu, Hao; Qin, Shuitao; Li, Bing; Luo, Changjun; Chen, Junan. (2024). Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(8), 1717-1733. https://doi.org/10.1007/s13300-024-01594-7